Mesdopetam
Dopamine D3 receptor antagonist
| Mesdopetam | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Mesdopetam is a chemical compound that acts as a selective antagonist of the dopamine receptor D3. It is being investigated for its potential therapeutic effects in the treatment of Parkinson's disease and dyskinesia.
Pharmacology[edit | edit source]
Mesdopetam is known for its high affinity for the dopamine receptor D3, which is a subtype of the dopamine receptor family. The D3 receptor is primarily located in the limbic system of the brain, an area associated with emotion and cognition. By antagonizing this receptor, mesdopetam may help modulate the dopaminergic system, which is often dysregulated in conditions like Parkinson's disease.
Mechanism of Action[edit | edit source]
The primary mechanism of action of mesdopetam involves blocking the D3 receptors. This blockade can lead to a reduction in the overactivity of dopaminergic pathways that are implicated in the development of dyskinesia, a common side effect of long-term levodopa therapy in Parkinson's disease patients. By selectively targeting the D3 receptor, mesdopetam aims to provide therapeutic benefits without affecting other dopamine receptor subtypes, potentially reducing side effects.
Therapeutic Use[edit | edit source]
Mesdopetam is currently under investigation for its use in managing levodopa-induced dyskinesia in Parkinson's disease. Dyskinesia is a significant challenge in the management of Parkinson's disease, as it can severely impact the quality of life. Mesdopetam's selective action on the D3 receptor offers a novel approach to mitigating these symptoms.
Development and Research[edit | edit source]
Research on mesdopetam is ongoing, with clinical trials being conducted to evaluate its efficacy and safety profile. The compound is being developed by pharmaceutical companies with the aim of providing a new treatment option for patients suffering from Parkinson's disease-related dyskinesia.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
